CSPC Pharmaceutical Group (HKG:1093) officially began a phase I clinical trial of the SYH2092 injection at the first center in China.
The drug has been developed for weight management in adult patients with obesity.
CSPC Pharmaceutical Group (HKG:1093) officially began a phase I clinical trial of the SYH2092 injection at the first center in China.
The drug has been developed for weight management in adult patients with obesity.
Comments